{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:05:16Z","timestamp":1777183516333,"version":"3.51.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Disseminated toxoplasmosis is an uncommon but highly lethal cause of hyperferritinemic sepsis after hematopoietic cell transplantation (HCT). We report two cases of disseminated toxoplasmosis from two centers in critically ill adolescents after HCT: a 19-year-old who developed fever and altered mental status on day +19 after HCT and a 20-year-old who developed fever and diarrhea on day +52 after HCT. Both patients developed hyperferritinemia with multiple organ dysfunction syndrome and profound immune dysregulation, which progressed to death despite maximal medical therapies. Because disseminated toxoplasmosis is both treatable and challenging to diagnose, it is imperative that intensivists maintain a high index of suspicion for <jats:italic>Toxoplasma gondii<\/jats:italic> infection when managing immunocompromised children, particularly in those with known positive <jats:italic>T. gondii<\/jats:italic> serologies.<\/jats:p>","DOI":"10.3389\/fped.2021.719679","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T04:41:57Z","timestamp":1628570517000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Immune Dysregulation Due to Toxoplasma gondii Reactivation After Allogeneic Hematopoietic Cell Transplant"],"prefix":"10.3389","volume":"9","author":[{"given":"Robert B.","family":"Lindell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia M.","family":"Alcamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Dulek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy S.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie L.","family":"Kitko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paisit","family":"Paueksakon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Chiotos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","article-title":"Toxoplasma gondii: from animals to humans","volume":"30","author":"Tenter","year":"2000","journal-title":"Int J Parasitol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4269\/ajtmh.2007.77.405","article-title":"Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade","volume":"77","author":"Jones","year":"2007","journal-title":"Am J Trop Med Hyg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3389\/fmicb.2017.00389","article-title":"Toxoplasma gondii infection in immunocompromised patients: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya","year":"2004","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/QCO.0000000000000169","article-title":"Toxoplasma prophylaxis in haematopoietic cell transplant recipients: a review of the literature and recommendations","volume":"28","author":"Gajurel","year":"2015","journal-title":"Curr Opin Infect Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/cid\/cit557","article-title":"Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter study","volume":"57","author":"Schmidt","year":"2013","journal-title":"Clin Infect Dis."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1086\/338827","article-title":"Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis","author":"Montoya","year":"2002","journal-title":"J Infect Dis."},{"key":"B8","first-page":"1","article-title":"Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association\/Infectious Diseases Society of America","volume":"53","year":"2004","journal-title":"MMWR Recomm Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1128\/JCM.03282-14","article-title":"Molecular diagnosis of toxoplasmosis in immunocompromised patients: a 3-year multicenter retrospective study","volume":"53","author":"Robert-Gangneux","year":"2015","journal-title":"J Clin Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e13242","DOI":"10.1111\/tid.13242","article-title":"Toxoplasma-induced hemophagocytic lymphohistiocytosis after haploidentical allogeneic stem cell transplantation","volume":"22","author":"Sanchez-Petitto","year":"2020","journal-title":"Transpl Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1034\/j.1399-3062.2001.003001024.x","article-title":"Disseminated toxoplasmosis after bone marrow transplantation: report of 9 cases","volume":"3","author":"De Medeiros","year":"2001","journal-title":"Transpl Infect Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/sj.bmt.1704989","article-title":"Hyponatremia as the presenting feature of cerebral toxoplasmosis","volume":"35","author":"Duzovali","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/pbc.20537","article-title":"Disseminated toxoplasmosis resulting in graft failure in a cord blood stem cell transplant recipient","volume":"48","author":"Goebel","year":"2007","journal-title":"Pediatr Blood Cancer."},{"key":"B15","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1399-3046.2007.00891.x","article-title":"Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation","volume":"12","author":"Megged","year":"2008","journal-title":"Pediatr Transplant."},{"key":"B16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/MPH.0b013e318257a15c","article-title":"Acute encephalopathy in the immune-compromised child: never forget toxoplasmosis","volume":"34","author":"Caselli","year":"2012","journal-title":"J Pediatr Hematol Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/tid.12344","article-title":"Cerebral toxoplasmosis in an adolescent post allogeneic hematopoietic stem cell transplantation: successful outcome by antiprotozoal chemotherapy and CD4+ T-lymphocyte recovery","volume":"17","author":"Kerl","year":"2015","journal-title":"Transpl Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/DAD.0000000000000072","article-title":"Cutaneous acquired toxoplasmosis in a child: a case report and review of the literature","volume":"37","author":"Rand","year":"2015","journal-title":"Am J Dermatopathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jfma.2016.06.001","article-title":"Toxoplasmosis presenting with a subtle maculopapular eruption in a child post hematopoietic stem cell transplantation","volume":"115","author":"Yang","year":"2016","journal-title":"J Formos Med Assoc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/bmt.2017.117","article-title":"Toxoplasmosis disease in paediatric hematopoietic stem cell transplantation: do not forget it still exists","volume":"52","author":"Decembrino","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.14411\/fp.2019.019","article-title":"Low seroprevalence and low incidence of infection with Toxoplasma gondii (Nicolle et Manceaux, 1908) in pediatric hematopoietic cell transplantation donors and recipients: polish nationwide study","volume":"66","author":"Czyzewski","year":"2019","journal-title":"Folia Parasitol (Praha)."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e13226","DOI":"10.1111\/tid.13226","article-title":"Toxoplasma gondii: how fatal is it in pediatric allogeneic bone marrow transplantation setting?","volume":"22","author":"Komitopoulou","year":"2020","journal-title":"Transpl Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nm0509-496","article-title":"The sepsis seesaw: tilting toward immunosuppression","volume":"15","author":"Hotchkiss","year":"2009","journal-title":"Nat Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/S0140-6736(14)60687-5","article-title":"The systemic immune response to trauma: an overview of pathophysiology and treatment","volume":"384","author":"Lord","year":"2014","journal-title":"Lancet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/01.shk.0000245033.69977.c5","article-title":"Alterations in inflammatory capacity and TLR expression on monocytes and neutrophils after cardiopulmonary bypass","volume":"27","author":"Hadley","year":"2007","journal-title":"Shock."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/PCC.0000000000001338","article-title":"High levels of morbidity and mortality among pediatric hematopoietic cell transplant recipients with severe sepsis: insights from the sepsis prevalence, outcomes, and therapies international point prevalence study","volume":"18","author":"Lindell","year":"2017","journal-title":"Pediatr Crit Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/CCM.0000000000004329","article-title":"Risk of mortality in immunocompromised children with severe sepsis and septic shock","volume":"48","author":"Lindell","year":"2020","journal-title":"Crit Care Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.chom.2011.04.015","article-title":"Toxoplasma polymorphic effectors determine macrophage polarization and intestinal inflammation","volume":"9","author":"Jensen","year":"2011","journal-title":"Cell Host Microbe."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0144507","DOI":"10.1371\/journal.pone.0144507","article-title":"Toxoplasma gondii chitinase induces macrophage activation","volume":"10","author":"Almeida","year":"2015","journal-title":"PLoS ONE."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e00139","DOI":"10.1128\/IAI.00139-19","article-title":"Persistent Toxoplasma infection of the brain induced neurodegeneration associated with activation of complement and microglia","volume":"87","author":"Li","year":"2019","journal-title":"Infect Immun."},{"key":"B31","article-title":"Red Book: 2021 Report of the Committee on Infectious Diseases","year":"2021"},{"key":"B32","unstructured":"Department of Health and Human Services"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1128\/AAC.42.6.1346","article-title":"Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group","volume":"42","author":"Torre","year":"1998","journal-title":"Antimicrob Agents Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.ophtha.2005.05.025","article-title":"Prospective randomized trial of trimethoprim\/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis","volume":"112","author":"Soheilian","year":"2005","journal-title":"Ophthalmology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/infdis\/157.3.580","article-title":"Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS","volume":"157","author":"Weiss","year":"1988","journal-title":"J Infect Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1128\/AAC.36.5.1040","article-title":"Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group","volume":"36","author":"Mcleod","year":"1992","journal-title":"Antimicrob Agents Chemother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.719679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T04:42:01Z","timestamp":1628570521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.719679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":37,"alternative-id":["10.3389\/fped.2021.719679"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.719679","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"article-number":"719679"}}